Sophia aims to parlay expertise of new backers aMoon, Hitachi to grow biopharma business

Genomics data company Sophia looked increasingly to healthcare investors when putting together the syndicate for its new $110 million series F round, which will go toward building the biopharma side of its business.

Sophia Genetics S.A. had largely been funded by tech investors, founder and CEO Jurgi Camblong told BioCentury. “For this round, we wanted to bring in healthcare investors who know the space, as well as who know strategic angles in that space.”...